Physician profile
Kumar P Patel
NPI 1760895437
$5,265.28
in general payments reported to CMS, 2019-2025
13 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $362 · 2021: $657 · 2022: $3,288 · 2023: $404 · 2024: $196 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,297.95 | 2020-2025 | Acuvue, Axert |
| Topcon Healthcare, INC. | $1,519.91 | 2022 | |
| Coopervision INC. | $571.10 | 2021-2025 | Myday Contact Lens, Misight Contact Lens |
| Allergan, INC. | $273.98 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $119.32 | 2021 | |
| Optos, INC. | $116.88 | 2020 | |
| Bausch & Lomb Americas INC. | $116.18 | 2024 | Miebo, Xiidra |
| Abbvie INC. | $76.90 | 2023 | |
| Abb Con-Cise Optical Group LLC | $75.00 | 2019 | |
| Shire North American Group INC | $26.61 | 2019 | |
| Sight Sciences, INC. | $25.31 | 2020 | |
| Biotissue Holdings INC. | $24.23 | 2019 | |
| Oyster Point Pharma, INC. | $21.91 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.